本发明属于医药技术领域,具体涉及一种抑制黄嘌呤氧化酶活性的化合物及其制备方法和应用。
背景技术:
尿酸是嘌呤代谢的产物,血液中尿酸水平长期升高被认为是引发痛风、心血管疾病、ii型糖尿病和慢性肾脏病(ckd)的重要因素。一般情况下,人体的尿酸处于动态平衡,而长期高嘌呤饮食或者肾功能损伤等因素将打破这种平衡,最终导致尿酸水平升高。黄嘌呤氧化酶是嘌呤代谢的限速酶,其催化次黄嘌呤氧化为黄嘌呤,并进一步将黄嘌呤氧化为尿酸,对其抑制可以减少体内尿酸的生成。因此,黄嘌呤氧化酶被认为是降尿酸的可靠靶标。目前已上市的黄嘌呤氧化酶抑制剂主要是别嘌呤醇和非布司他。别嘌呤醇作为最经典的黄嘌呤氧化酶抑制剂,几十年来一直是降尿酸的首选药物。然而,在某些情况下,别嘌呤醇具有严重威胁生命的副作用。非布司他是一种强效的黄嘌呤氧化酶抑制剂,常被用于别嘌呤醇无效患者的治疗,但长期安全性显示该药物具有一定的心脏毒性。因此,研制高效低毒的黄嘌呤氧化酶抑制剂具有良好的应用前景。
技术实现要素:
针对现有技术存在的问题,本发明提供一种抑制黄嘌呤氧化酶活性的化合物、该化合物的异构体、在药学上可接受的盐或溶剂化物,另外还提供该化合物的制备方法和其在制备抗痛风药物中的用途。
本发明的首要目的在于提供一种抑制黄嘌呤氧化酶活性的化合物,其为如通式i所示的化合物、或是该化合物的异构体、或是该化合物在药学上可接受的盐或溶剂化物。
本发明的另一目的在于提供一种抑制黄嘌呤氧化酶活性的化合物的制备方法。
本发明的再一目的在于提供上述化合物或该化合物在药学上可接受的盐在制备用于治疗和/或预防高尿酸血症和痛风病的药物中的应用。
所述的通式i为:
其中,r1为h、c1-c6烷基、c2-c6烯基、取代或未取代的苄基;所述的用于取代的取代基为卤素或c1-c6烷基。
r2为h、甲基、chf2、cf3、nh2或oh。
进一步的,一种抑制黄嘌呤氧化酶活性的化合物,其为下述化合物x-1~x-26和xx-1~xx-29中的任一种或是该化合物的异构体、在药学上可接受的盐、溶剂化物;其中:
x-1~x-26和xx-1~xx-29为:
x-1~x-26和xx-1~xx-29为:
x-1:2-[(3-氰基-4-苄氧基)苯基]-5-嘧啶甲酸
x-2:2-[(3-氰基-4-羟基)苯基]-5-嘧啶甲酸
x-3:2-[(3-氰基-4-丙氧基)苯基]-5-嘧啶甲酸
x-4:2-[(3-氰基-4-丁氧基)苯基]-5-嘧啶甲酸
x-5:2-[(3-氰基-4-异丙氧基)苯基]-5-嘧啶甲酸
x-6:2-[(3-氰基-4-异丁氧基)苯基]-5-嘧啶甲酸
x-7:2-[(3-氰基-4-异戊氧基)苯基]-5-嘧啶甲酸
x-8:2-[(3-氰基-4-环丙氧基)苯基]-5-嘧啶甲酸
x-9:2-[(3-氰基-4-环己甲氧基)苯基]-5-嘧啶甲酸
x-10:2-[(3-氰基-4-烯丙氧基)苯基]-5-嘧啶甲酸
x-11:2-[(3-氰基-4-炔丙氧基)苯基]-5-嘧啶甲酸
x-12:2-{[3-氰基-4-(3-甲基丁-2-烯-1-基)氧基]苯基}-4-甲基-5-嘧啶甲酸
x-13:2-[3-氰基-4-(甲氧甲氧基)苯基]-5-嘧啶甲酸
x-14:2-{[3-氰基-4-(2-羟基乙基)氧基]苯基}-5-嘧啶甲酸
x-15:2-{[3-氰基-4-(四氢-2h-吡喃-4-基)甲氧基]苯基}-5-嘧啶甲酸
x-16:2-{[3-氰基-4-(吡啶-4-基甲)氧基]苯基}-5-嘧啶甲酸
x-17:2-{[3-氰基-4-(4-甲氧基苄基)氧基]苯基}-5-嘧啶甲酸
x-18:2-{[3-氰基-4-(4-叔丁基苄基)氧基]苯基}-5-嘧啶甲酸
x-19:2-{[3-氰基-4-(4-氟苄基)氧基]苯基}-5-嘧啶甲酸
x-20:2-{[3-氰基-4-(4-氯苄基)氧基]苯基}-5-嘧啶甲酸
x-21:2-{[3-氰基-4-(4-溴苄基)氧基]苯基}-5-嘧啶甲酸
x-22:2-{[3-氰基-4-(4-甲基苄基)氧基]苯基}-5-嘧啶甲酸
x-23:2-{[3-氰基-4-(3-氟苄基)氧基]苯基}-5-嘧啶甲酸
x-24:2-{[3-氰基-4-(3-氯苄基)氧基]苯基}-5-嘧啶甲酸
x-25:2-{[3-氰基-4-(2-氟苄基)氧基]苯基}-5-嘧啶甲酸
x-26:2-{[3-氰基-4-(2-氯苄基)氧基]苯基}-5-嘧啶甲酸
xx-1:2-[(3-氰基-4-丙氧基)苯基]-4-甲基-5-嘧啶甲酸
xx-2:2-[(3-氰基-4-丁氧基)苯基]-4-甲基-5-嘧啶甲酸
xx-3:2-[(3-氰基-4-异丙氧基)苯基]-4-甲基-5-嘧啶甲酸
xx-4:2-[(3-氰基-4-异丁氧基)苯基]-4-甲基-5-嘧啶甲酸
xx-5:2-[(3-氰基-4-异戊氧基)苯基]-4-甲基-5-嘧啶甲酸
xx-6:2-[(3-氰基-4-环丙氧基)苯基]-4-甲基-5-嘧啶甲酸
xx-7:2-[(3-氰基-4-环己甲氧基)苯基]-4-甲基-5-嘧啶甲酸
xx-8:2-[(3-氰基4-烯丙氧基)苯基]-4-甲基-5-嘧啶甲酸
xx-9:2-[(3-氰基-4-苄氧基)苯基]-4-甲基-5-嘧啶甲酸
xx-10:2-{[3-氰基-4-(4-叔丁基苄基)氧基]苯基}-4-甲基-5-嘧啶甲酸
xx-11:2-{[3-氰基-4-(4-氟苄基)氧基]苯基}-4-甲基-5-嘧啶甲酸
xx-12:2-{[3-氰基-4-(4-氯苄基)氧基]苯基}-4-甲基-5-嘧啶甲酸
xx-13:2-{[3-氰基-4-(4-溴苄基)氧基]苯基}-4-甲基-5-嘧啶甲酸
xx-14:2-{[3-氰基-4-(4-甲基苄基)氧基)]苯基}-4-甲基-5-嘧啶甲酸
xx-15:2-{[3-氰基-4-(4-氰基苄基)氧基]苯基}-4-甲基-5-嘧啶甲酸
xx-16:2-{[3-氰基-4-(3-氟苄基)氧基]苯基}-4-甲基-5-嘧啶甲酸
xx-17:2-{[3-氰基-4-(3-氯苄基)氧基]苯基}-4-甲基-5-嘧啶甲酸
xx-18:2-{[3-氰基-4-(3-溴苄基)氧基]苯基}-4-甲基-5-嘧啶甲酸
xx-19:2-{[3-氰基-4-(3-甲基苄基)氧基]苯基}-4-甲基-5-嘧啶甲酸
xx-20:2-{[3-氰基-4-(3-氰基苄基)氧基]苯基}-4-甲基-5-嘧啶甲酸
xx-21:2-{[3-氰基-4-(2-氟苄基)氧基]苯基}-4-甲基-5-嘧啶甲酸
xx-22:2-{[3-氰基-4-(2-氯苄基)氧基]苯基}-4-甲基-5-嘧啶甲酸
xx-23:2-{[3-氰基-4-(2-溴苄基)氧基]苯基}-4-甲基-5-嘧啶甲酸
xx-24:2-{[3-氰基-4-(2-甲基苄基)氧基]苯基}-4-甲基-5-嘧啶甲酸
xx-25:2-{[3-氰基-4-(2-氰基苄基)氧基]苯基}-4-甲基-5-嘧啶甲酸
xx-26:2-[3-(氰基-4-异戊氧基)苯基]-4-二氟甲基-5-嘧啶甲酸
xx-27:2-{[3-氰基-4-(4-甲氧基苄基)氧基]苯基}-4-二氟甲基-5-嘧啶甲酸
xx-28:2-[3-(氰基-4-异丁氧基)苯基]-4-三氟甲基-5-嘧啶甲酸
xx-29:2-[3-(氰基-4-异戊氧基)苯基]-4-三氟甲基-5-嘧啶甲酸
x-1~x-26和xx-1~xx-29的具体结构分别为:
本发明还提供了一种如通式ii所示的中间体化合物,用于制备所述x-1~x-26和xx-1~xx-29化合物中的任一种;
其中,r1为h、c1-c6烷基、c2-c6烯基、取代或未取代的苄基,所述的用于取代的取代基为卤素或c1-c6烷基;
进一步的,所述中间体化合物为下述化合物2-3-1~2-3-25中的任一种;
所述的异构体包括但不限于:立体异构体、几何异构体和互变异构体。
所述的化合物在药学上可接受的盐,是指本发明所述化合物的有机盐和无机盐包括,但并不限于:钠盐、钾盐和氨盐。
所述的化合物的溶剂化物,是指一个或多个溶剂分子与本发明所述化合物所形成的缔合物。形成溶剂化物的溶剂包括但不限于:水、甲醇、乙醇、二甲亚砜、乙酸乙酯、四氢呋喃、二氯甲烷、甲苯和dmf。
本发明还提供了所述抑制黄嘌呤氧化酶活性的化合物x-1~x-26和xx-1~xx29的制备方法,包括:
(1)化合物x-1~x-26的制备方法,具体包括:
步骤1:以3-氰基-4-苄氧基-苯甲脒(sm1)为起始原料,在乙醇回流条件下与2-甲酰基-3-氧代丙酸乙酯按1:(0.1~10)的摩尔比环合制得2-{3-氰基-4-[(4-甲氧基苄基)氧基]苯基}-嘧啶-5-羧酸乙酯,其在40-100℃乙醇/水条件下经naoh水解得到中间体化合物1-1,得到的化合物1-1同时也是本发明化合物x-1;
步骤2:中间体化合物1-1在50℃和pd/c催化条件下加h2反应,得到中间体化合物1-2,得到的化合物1-2同时也是本发明化合物x-2;;
步骤3:中间体化合物1-2在20-160℃条件下与相应烃化试剂按1:(0.1~10)的摩尔比反应,在经naoh水解得到相应的化合物x-3~x-26。
x-1~x-26的制备路径为:
(2)化合物xx-1~xx-25的制备方法,具体包括:
步骤1:以3-氰基-4-苄氧基-苯甲脒(sm1)为起始原料,在甲苯回流条件下与(z/e)-2-[(二甲氨基)亚甲基]-3-氧代丁酸叔丁酯按1:(0.1~10)的摩尔比环合,生成化合物2-1;
步骤2:化合物2-1在20-50℃和pd/c催化条件下加h2反应,得到化合物2-2;
步骤3:化合物2-2在20-160℃条件下与相应烃化试剂按1:(0.1~10)的摩尔比反应,得到相应的中间体化合物2-3-1~2-3-25;
步骤4:中间体化合物2-3-1~2-3-25在室温下与三氟乙酸按1:(1~100)的摩尔比反应,得到相应的化合物xx-1~xx-25。
xx-1~xx-25的制备路径为:
(3)化合物xx-26~xx-29的制备方法,具体包括:
步骤1:以相应的3-氰基-4-烷氧基-苯甲脒(sm2)为起始原料,在甲苯回流条件下与(z/e)-2-[(二甲氨基)亚甲基]-4,4-二氟-3-氧代丁酸苄酯或(z/e)-2-[(二甲氨基)亚甲基]-4,4,4-三氟-3-氧代丁酸苄酯按1:(0.1~10)的摩尔比环合,得到相应的化合物3-1;
步骤2:所得化合物3-1经naoh水解得到相应的化合物xx-26~xx-29。
xx-26~xx-29的制备路径为:
本发明提供了一种药物组合物,其包含本发明所述的具有抑制黄嘌呤氧化酶活性的化合物、该化合物的异构体、该化合物在药学上可接受的盐或溶剂化物中的一种或多种;还包括药学上可接受的辅料、载体、稀释剂中的一种或它们的组合。所述药物组合物的给药途径包括:口服、鼻腔、经皮、肺部及肠胃外给药,优选通过口服途径给药。具体为,只要其有效地将活性药物传送到所需的活性部位,如直肠、贮库、皮下、静脉内、尿道内、肌肉内、鼻内、眼用溶液或油膏途径给药。所述药物组合物的剂型包括:片剂、胶囊剂、锭剂、糖浆剂、乳剂、注射剂、气溶胶及糖衣丸。所述药物组合物中具有抑制黄嘌呤氧化酶活性的化合物的重量百分比为0.5-20%,优选0.5-10%。
含有本发明化合物的药物组合物可以通过常规方法制备,例如在remington:thescienceandpracticeofpharmacy,19thed.,1995中描述。具体为,该组合物可以是常规的剂型如胶囊、片剂、粉末、溶液、混悬液、糖浆、气溶胶或局部给药形式。它们可以含有适当的固体或液体载体在适当的无菌介质中形成注射溶液或混悬液。
所述的载体为水、盐溶液、醇、聚乙二醇、聚羟基乙氧基化蓖麻油、花生油、椰揽油、明胶、乳糖、石膏粉、蔗糖、环糊精、直链淀粉、硬脂酸镁(magnesiumsterate)、滑石、明胶、琼脂、果胶、阿拉伯胶、硬脂酸或纤维素的低级烷基醚、硅酸、脂肪酸、脂肪酸胺、脂肪酸甘油单酯和甘油二酯、季成四醇脂肪酸酯、聚氧乙烯、羟基甲基纤维素及聚乙烯吡咯烷酮中的任一种或多种。制剂中还可以包括润湿剂、乳化剂、混悬剂、防腐剂、甜味剂或增香剂。可以通过本领域己知的方法配制本发明的制剂,以提供活性成分给药患者后的快速、持续或延迟释放。
所述药物组合物可以是无菌的,并且如果有需要可以与辅料、乳化剂、缓冲剂和/或着色剂等混合,只要其不与活性化合物反应。
对于鼻内给药,该制剂可以含有溶解或混悬于液体载体,尤其是水性载体中的气溶胶给药。该载体可以含有添加剂,包括增溶剂如丙二醇,表面活性剂,吸收促进剂如卵磷脂(磷脂酚胆碱)或环糊精,防腐剂如对羟基苯甲酸酯类。
对于肠胃外给药,特别适合的是注射溶液或混悬液,优选活性化合物溶剂于多羟基化蓖麻油中的水性溶液。
具有滑石和/或碳水化合物载体或粘合剂的片剂、糖衣丸或胶囊特别适合于口服给药。片剂、糖衣丸或胶囊的载体包括乳糖、玉米淀粉和/或马铃薯淀粉。当可以使用加糖载体时,可以使用糖浆剂或酗剂。
一种抑制黄嘌呤氧化酶活性的化合物或该化合物在药学上可接受的盐或上述药物组合物在制备用于治疗和/或预防高尿酸血症和痛风病的药物中的应用。
黄嘌呤氧化酶是嘌呤代谢的限速酶,其催化次黄嘌呤氧化为黄嘌呤,并进一步将黄嘌呤氧化为尿酸,对其抑制可以减少体内尿酸的生成。因此,黄嘌呤氧化酶被认为是降尿酸的可靠靶标。
本发明的有益效果:
本发明化合物的结构新颖,在对嘧啶环上的取代基进行考察时,发现5位羧基的有无对黄嘌呤氧化酶的抑制活性至关重要,甲基的引入可提高化合物的活性,而二氟甲基或三氟甲基的引入使活性显著下降,因此本发明为新型的非嘌呤类黄嘌呤氧化酶抑制剂的设计提供了思路。同时本发明的合成方法具有操作简捷,收率高,产品易于纯化。
具体实施方式
实施例1
抑制黄嘌呤氧化酶活性的化合物x-1~x-3的制备方法,包括以下步骤:
步骤1:向反应瓶中依次加入(10g,40mmol)3-氰基-4-苄氧基-苯脒(sm1)、(6.2g,43mmol)2-甲酰基-3-氧代丙酸乙酯和60ml无水乙醇,升温至回流,搅拌24h,tlc监测反应,反应结束,加入15ml4mnaoh进行水解,tlc监测反应,反应结束,向反应液中加入2mhcl调ph=5左右,降温析晶、抽滤、滤饼用50%的乙醇水浆洗,抽滤,滤饼在60℃鼓风干燥,得3.3g类白色固体,即中间体化合物1-1,收率为25.4%,得到的中间体化合物1-1同时也是本发明所述化合物x-1;
步骤2:向反应瓶中依次加入(5g,15.1mmol)中间体化合物1-1、(10%,1g)pd/c、10mldmf和50mlthf,通入h2置换两次,升温至50℃搅拌8h,tlc监测反应,反应结束,浓缩除去thf,向反应液中加入50ml水,用稀盐酸调ph=4左右,有大量白色固体析出,抽滤,滤饼60℃鼓风干燥,得3.1g中间体化合物1-2粗品,用乙醇/水(v:v=1:1)打浆纯化,得到2.2g中间体化合物1-2精制品,收率59.3%,得到的中间体化合物1-2也是本发明所述化合物x-2;
步骤3:向反应瓶中依次加入(0.2g,0.8mmol)中间体化合物1-2、(0.25g,1.8mmol)溴代正丙基、(0.29g,2.1mmol)k2co3、0.01gki和10mldmf,升温至60℃搅拌8h,tlc监测反应,反应结束,加入4ml2mnaoh,tlc监测反应,反应结束,加入2mhcl调ph=5左右,降温析晶,抽滤,滤饼用75%的乙醇水浆洗,抽滤,滤饼用60℃鼓风干燥,得0.11g类白色固体,即目的化合物x-3,收率为62.1%。
对上述过程中制得的中间体及产物进行熔点、核磁及质谱检测,具体如下:
1-1(x-1):m.p.256-257℃.1hnmr(400mhz,dmso)δ(ppm):13.78(s,0h),9.27(s,1h),8.80–8.53(m,1h),7.72–7.23(m,4h),5.40(d,j=6.8hz,1h).13cnmr(100mhz,)δ(ppm):165.27,164.25,162.80,159.04,136.12,135.37,134.15,129.91,129.10,128.77,128.16,123.06,116.26,114.58,102.09,71.15.esi-ms:m/z330.0895[m-h]-.
1-2(x-2):m.p.285-290℃.1hnmr(400mhz,dmso)δ(ppm):9.24(s,2h),8.72–8.39(m,2h),7.19(d,j=8.8hz,1h).13cnmr(150mhz,dmso)δ(ppm):165.86,164.36,163.66,158.97,135.12,134.07,128.23,117.31,116.95,100.12.esi-ms:m/z240.0423[m-h]-.
x-3:m.p.271-282℃.1hnmr(400mhz,dmso)δ(ppm):13.76(s,1h),9.25(s,2h),8.87–8.49(m,2h),7.43(d,j=9.0hz,1h),4.21(t,j=6.4hz,2h),1.82(dd,j=14.0,6.9hz,2h),1.03(t,j=7.4hz,3h).13cnmr(100mhz,dmso)δ(ppm):165.28,164.28,163.15,159.01,135.42,134.07,129.51,123.00,116.23,114.04,100.78,71.20,22.21,10.59.esi-ms:m/z282.0911[m-h]-.
采用实施例1的方法制备化合物x-4~x-26。对制备得到的化合物进行熔点、核磁及质谱检测,具体如下:
x-4:m.p.273-275℃.1hnmr(400mhz,dmso)δ(ppm)13.75(s,1h),9.26(s,2h),8.83–8.31(m,2h),7.45(d,j=9.0hz,1h),4.26(t,j=6.4hz,2h),1.94–1.68(m,2h),1.49(dd,j=14.9,7.4hz,2h),0.97(t,j=7.4hz,3h).13cnmr(100mhz,dmso)δ(ppm)165.28,164.31,163.18,159.03,135.44,134.08,129.53,123.01,116.25,114.07,100.79,69.58,30.80,19.02,14.08.esi-ms:m/z296.1070[m-h]-.
x-5:m.p.202-203℃.1hnmr(400mhz,dmso)δ(ppm):9.25(s,2h),8.75–8.39(m,2h),7.45(d,j=9.1hz,1h),5.08–4.73(m,1h),1.38(d,j=6.0hz,6h).13cnmr(100mhz,dmso)δ(ppm):165.26,164.28,162.25,158.99,135.29,134.27,129.29,122.94,116.39,114.85,102.43,72.58,22.03.esi-ms:m/z282.0910[m-h]-.
x-6:m.p.197-198℃.1hnmr(400mhz,dmso)δ(ppm):13.80(s,1h),9.25(m,j=5.6hz,2h),8.77–8.53(m,2h),7.45(d,j=9.0hz,1h),4.04(d,j=6.5hz,2h),2.11(m,1h),1.03(d,j=6.7hz,6h).13cnmr(100mhz,dmso)δ(ppm):165.21,164.28,163.22,159.02,135.45,134.01,129.56,123.08,116.18,114.14,100.79,75.62,28.06,19.18.esi-ms:m/z296.1058[m-h]-.
x-7:m.p.204-205℃.1hnmr(400mhz,dmso)δ(ppm):9.27(s,2h),8.79–8.47(m,2h),7.47(d,j=9.0hz,1h),4.28(t,j=6.6hz,2h),1.84(dt,j=13.3,6.7hz,1h),1.71(q,j=6.6hz,2h),0.97(d,j=6.6hz,6h).13cnmr(100mhz,dmso)δ(ppm):165.28,164.31,163.17,159.03,135.42,134.08,129.52,122.99,116.25,114.07,100.79,68.44,37.44,25.11,22.85.esi-ms:m/z310.1224[m-h]-.
x-8:m.p.266-267℃.1hnmr(400mhz,dmso)δ(ppm):13.74(s,1h),9.26(s,2h),8.85–8.50(m,2h),7.42(d,j=8.7hz,1h),4.13(d,j=7.0hz,2h),1.48–1.05(m,1h),0.78–0.53(m,2h),0.42(q,j=4.5hz,2h).13cnmr(150mhz,dmso)δ(ppm):165.30,164.28,163.15,159.04,135.39,134.14,129.45,123.00,116.40,114.21,100.75,74.30,10.20,3.60.esi-ms:m/z294.0907[m-h]-.
x-9:m.p.260-261℃.1hnmr(400mhz,dmso)δ(ppm):13.76(s,1h),9.27(s,1h),8.83–8.17(m,1h),7.45(d,j=8.9hz,1h),4.07(d,j=5.6hz,2h),1.99–1.56(m,4h),1.37–0.95(m,3h).13cnmr(100mhz,dmso)δ(ppm):165.29,164.31,163.28,159.04,135.45,134.05,129.53,123.03,116.21,114.11,100.78,74.67,37.29,29.35,26.44,25.62.esi-ms:m/z336.1382[m-h]-.
x-10:m.p.235-236℃.1hnmr(400mhz,dmso)δ(ppm):13.78(s,1h),9.27(s,2h),8.67(m,2h),7.46(s,1h),6.10(m,1h),5.50(m,1h),5.37(s,1h),4.86(d,2h).13cnmr(150mhz,dmso)δ(ppm):165.29,164.24,162.64,159.05,135.34,134.12,132.75,129.77,123.05,118.87,116.25,114.37,100.88,70.06.esi-ms:m/z280.0750[m-h]-.
x-11:m.p.270-274℃.1hnmr(400mhz,dmso)δ(ppm)13.79(s,1h),9.27(s,2h),8.81–8.37(m,2h),7.51(d,j=9.0hz,1h),5.14(d,j=2.2hz,2h),3.76(s,1h).13cnmr(150mhz,dmso)δ(ppm)165.30,164.12,161.69,159.07,135.21,134.20,130.42,123.32,116.09,116.27,114.61,102.12,80.25,78.30,57.07.esi-ms:m/z278.0570[m-h]-.
x-12:m.p.210-213℃.1hnmr(400mhz,dmso)δ(ppm)9.23(s,2h),8.77–8.47(m,2h),7.44(d,j=9.0hz,1h),5.49(t,j=6.7hz,1h),4.81(d,j=6.7hz,2h),1.78(d,j=7.5hz,6h).13cnmr(100mhz,dmso)δ(ppm)165.48,163.55,162.78,158.93,139.52,135.13,133.92,130.08,129.82,118.95,116.43,114.30,100.78,66.64,25.92,18.61.esi-ms:m/z308.1071[m-h]-.
x-13:m.p.239-240℃.1hnmr(400mhz,dmso)δ(ppm)9.21(s,2h),8.76–8.48(m,2h),7.50(d,j=9.7hz,1h),5.47(s,2h),3.47(s,4h).13cnmr(100mhz,dmso)δ(ppm)174.29,162.85,160.98,158.82,134.91,133.72,131.18,116.28,115.92,102.58,95.26,56.81.esi-ms:m/z374.2[m+h]+.esi-ms:m/z284.0684[m-h]-.
x-14:m.p.274-275℃.1hnmr(400mhz,dmso)δ(ppm):13.77(s,1h),9.26(s,2h),8.66(m,2h),7.47(d,j=8.4hz,1h),4.99(s,1h),4.29(s,2h),3.81(s,2h).13cnmr(150mhz,dmso)δ(ppm):165.30,164.26,163.28,159.03,135.35,134.17,129.52,122.99,116.38,114.18,100.80,71.72,59.69.esi-ms:m/z284.0678[m-h]-.
x-15:m.p.262-263℃.1hnmr(400mhz,dmso)δ(ppm):13.78(s,1h),9.27(s,2h),8.95–8.40(m,2h),7.46(d,j=9.0hz,1h),4.13(d,j=6.4hz,2h),3.91(m,2h),3.38(m,h),2.22–2.02(m,1h),1.71(d,j=12.7hz,2h),1.41(m,2h).13cnmr(150mhz,dmso)δ(ppm):165.31,164.26,163.12,159.06,135.45,134.04,129.63,123.08,116.17,114.12,100.78,73.91,67.00,34.70,29.33.esi-ms:m/z338.1170[m-h]-.
x-16:m.p.284-289℃.1hnmr(400mhz,dmso)δ(ppm):9.27(s,2h),8.80–8.67(m,2h),8.62(d,j=4.7hz,1h),7.91(m,,2h),7.58(m,2h),7.40(m,1h),5.48(s,2h).13cnmr(150mhz,dmso)δ(ppm):165.30,164.13,162.62,159.06,155.76,149.79,137.74,135.39,134.13,130.12,123.82,122.10,116.28,114.63,102.04,71.84.esi-ms:m/z331.0826[m-h]-.
x-17:m.p.231-232℃.1hnmr(400mhz,dmso)δ(ppm):13.74(s,1h),9.27(s,2h),8.77–8.59(m,2h),7.58(d,j=9.0hz,1h),7.45(d,j=8.6hz,2h),7.00(d,j=8.6hz,2h),5.32(s,2h),3.77(s,3h).13cnmr(150mhz,dmso)δ(ppm):165.28,164.26,162.89,159.85,159.05,135.33,134.14,130.22,129.75,127.90,123.02,116.31,114.61,114.49,102.03,71.06,55.61.esi-ms:m/z360.1018[m-h]-.
x-18:m.p.270-272℃.1hnmr(400mhz,dmso)δ(ppm):9.27(s,2h),8.77–8.50(m,2h),7.57(d,j=8.9hz,1h),7.53–7.33(m,4h),5.36(s,2h),1.30(d,j=4.1hz,9h).13cnmr(150mhz,dmso)δ(ppm):165.30,164.23,162.88,159.07,150.34,135.40,134.17,133.08,129.84,128.19,125.88,123.16,116.31,114.55,102.01,71.03,34.84,31.56.esi-ms:m/z386.1522[m-h]-.
x-19:m.p.290-292℃.1hnmr(400mhz,dmso)δ(ppm):9.26(s,2h),8.70(m,2h),7.57(m,2h),7.33–7.12(m,2h),5.39(s,2h).esi-ms:m/z374.2[m+h]+.13cnmr(150mhz,dmso)δ(ppm):165.32,164.07,163.32,162.65,161.70,159.04,135.36,134.12,132.38,132.36,130.62,130.56,130.02,123.55,116.26,116.06,115.91,114.56,102.05,70.45.esi-ms:m/z348.0792[m-h]-.
x-20:m.p.282-285℃.1hnmr(400mhz,dmso)δ(ppm):9.20(s,2h),8.67(m,2h),7.70–7.20(m,5h),5.39(s,2h).13cnmr(150mhz,dmso)δ(ppm):165.26,164.17,162.57,159.02,135.35,135.14,134.12,133.41,129.98,129.12,123.04,116.19,114.49,102.05,70.27.esi-ms:m/z364.0522[m-h]-.
x-21:m.p.290.0℃.1hnmr(400mhz,dmso)δ(ppm):9.26(s,2h),8.79–8.42(m,2h),7.65(d,j=8.3hz,2h),7.54(d,j=8.7hz,1h),7.48(d,j=8.3hz,2h),5.39(s,1h).13cnmr(150mhz,dmso)δ(ppm):165.33,163.93,162.52,159.01,135.60,135.33,134.09,132.07,130.33,130.13,123.88,121.98,116.23,114.55,102.05,70.32.esi-ms:m/z407.9996[m-h]-.
x-22:m.p.239-240℃.1hnmr(400mhz,dmso)δ(ppm):9.23(s,2h),8.66(d,j=10.4hz,2h),7.53(d,j=8.8hz,1h),7.40(d,j=7.6hz,2h),7.24(d,j=7.6hz,2h),5.34(s,2h),2.32(s,3h).13cnmr(150mhz,dmso)δ(ppm):166.10,162.21,162.05,158.68,138.12,134.79,133.50,133.14,130.63,129.63,128.37,116.45,114.35,104.72,100.79,71.00,21.27.esi-ms:m/z344.1059[m-h]-.
x-23:m.p.>290℃.1hnmr(400mhz,dmso)δ(ppm):9.20(s,2h),8.69(m,2h),7.51(m,2h),7.36(d,j=8.2hz,2h),7.22(m,1h),5.42(s,2h).13cnmr(100mhz,dmso)δ(ppm):165.68,163.89,163.07,162.23,161.44,158.82,139.10,135.14,133.83,131.22,130.52,123.99,116.28,115.62,114.83,114.62,114.42,102.00,70.19.esi-ms:m/z348.0811[m+h]+.
x-24:m.p.285-290℃.1hnmr(400mhz,dmso)δ(ppm):9.21(s,1h),8.68(m,2h),7.60(s,1h),7.53–7.32(m,4h),5.41(s,2h).13cnmr(150mhz,dmso)δ(ppm):165.67,163.21,162.25,158.84,138.71,135.18,133.88,133.71,131.04,130.45,128.67,127.84,126.65,125.82,116.28,114.41,101.98,70.11.esi-ms:m/z364.0512[m-h]-.
x-25:m.p.257-258℃.1hnmr(400mhz,dmso)δ(ppm):13.77(s,1h).9.26(s,2h),8.82–8.56(m,2h),7.63(m,2,1h),7.48(m,1h),7.31(m,2h),5.45(s,1h).13cnmr(150mhz,dmso)δ(ppm):165.29,164.20,162.55,161.70,160.06,159.07,135.42,134.18,131.43,131.37,131.04,131.02,130.10,125.20,125.18,123.11,123.07,122.97,116.14,116.12,115.98,114.49,102.04,65.70,65.68.esi-ms:m/z348.0802[m-h]-.
x-26:m.p.275-277℃.1hnmr(400mhz,dmso)δ(ppm):9.28(s,1h),8.79–8.54(m,2h),7.69(dd,j=5.6,3.7hz,1h),7.65–7.53(m,2h),7.49–7.37(m,2h),5.45(s,2h).13cnmr(150mhz,dmso)δ(ppm):165.29,164.16,162.49,159.05,135.45,134.16,133.49,133.17,130.81,130.48,130.14,130.04,128.00,123.15,116.14,114.46,102.02,68.80.esi-ms:m/z364.0493[m-h]-.
实施例2
抑制黄嘌呤氧化酶活性的化合物xx-1的制备方法,包括以下步骤:
步骤1:向反应瓶中依次加入(10g,39.8mmol)3-氰基-4-苄氧基-苯脒(sm1)、(10.2g,47.9mmol)(z/e)-2-[(二甲基氨基)亚甲基]-3-氧代丁酸叔丁酯和100ml甲苯,升温至回流搅拌6h,tlc监测反应,反应结束,浓缩除去溶剂,向反应液中加入100ml甲醇,在50℃搅拌30min,降温、抽滤、滤饼用60℃鼓风干燥,得11g白色固体化合物2-1,收率为68.9%;
步骤2:向反应瓶中依次加入(10g,0.0249mol)化合物2-1、(10%,1g)pd/c、50mldmf,同时通入氢气h2置换两次,升温至45℃搅拌8h,tlc监测反应,反应结束,抽滤,向滤液中加入150ml水,在室温搅拌1h,抽滤、滤饼用60℃鼓风干燥,得6.8g白色固体化合物2-2,收率为87.8%;
步骤3:向反应瓶中依次加入(0.2g,0.0006mol)化合物2-2、(0.12g,0.001mol)溴代正丙烷、(0.14g,0.001mol)k2co3、0.01gki和5mldmf,升温至50℃搅拌24h,tlc监测反应,反应结束,向反应液中加入20mlh2o和20mlea,静置分层,有机层经无水硫酸钠干燥,经柱层析分离得0.10g油状物,即中间体化合物2-3-1,收率为47%;
步骤4:向反应瓶中依次加入(0.2g,0.6mmol)中间体化合物2-3-1和5ml三氟乙酸,在室温下搅拌1h,tlc监测反应,反应结束,减压浓缩除去溶剂,向反应液中加入10mlh2o,室温下搅拌30min,抽滤,滤饼60℃鼓风干燥,得0.15g白色固体,即化合物xx-1粗品,收率为89.3%。所得粗品用乙酸乙酯重结晶得0.1g化合物xx-1精制品。
对上述过程中制得的中间体及产物进行检测,具体如下:
2-1:m.p.133-136℃.1hnmr(400mhz,dmso)δ(ppm):9.10(s,1h),8.67(m,2h),7.46(m,6h),5.40(s,2h),2.78(s,3h),1.59(s,9h).esi-ms:m/z402.2[m+h]+.
2-2:m.p.80℃.1hnmr(600mhz,dmso)δ(ppm):9.21(s,1h),8.56(dd,j=9.0,2.2hz,1h),8.52(d,j=2.3hz,1h),7.45(d,j=9.1hz,1h),4.39(q,j=7.1hz,2h),4.27(t,j=6.6hz,2h),1.84(m,j=,1h),1.70(q,j=6.7hz,2h),1.37(t,j=7.1hz,3h),0.97(d,j=6.7hz,6h).esi-ms:m/z311.2[m+h]+.
2-3-1:1hnmr(400mhz,dmso)δ(ppm):9.08(s,1h),8.76–8.49(m,2h),7.41(d,j=8.9hz,1h),4.20(t,j=6.5hz,2h),2.77(s,3h),1.82(dd,j=14.0,6.7hz,2h),1.03(t,j=7.4hz,3h).esi-ms:m/z354.2[m+h]+.
xx-1:m.p.219-220℃.1hnmr(400mhz,dmso)δ(ppm):13.60(s,1h),9.14(s,1h),8.66(m,2h),7.42(d,j=8.9hz,1h),4.21(m,2h),2.81(s,3h),1.82(m,2h),1.03(t,j=7.4hz,3h).13cnmr(150mhz,dmso)δ(ppm):168.97,166.48,162.99,162.71,159.68,135.33,133.95,129.55,122.31,116.33,113.93,100.64,71.14,24.79,22.22,10.62.esi-ms:m/z296.1051[m-h]-.
采用实施例2的方法制备化合物xx-~xx-8,xx-10~xx-25。对制备过程中制得的中间体及对应的产物进行检测,具体如下:
2-3-2:1hnmr(400mhz,dmso)δ(ppm):9.09(s,1h),8.64(m,2h),7.43(d,j=9.0hz,1h),4.25(t,j=6.4hz,2h),2.89–2.62(m,3h),1.78(dd,j=8.3,6.5hz,2h),1.59(s,9h),1.49(m,2h),0.97(t,j=7.4hz,3h).esi-ms:m/z368.2[m+h]+.
2-3-3:1hnmr(600mhz,dmso)δ(ppm):9.21(s,1h),8.56(dd,j=9.0,2.2hz,1h),8.52(d,j=2.3hz,1h),7.45(d,j=9.1hz,1h),4.39(q,j=7.1hz,2h),4.27(t,j=6.6hz,2h),1.84(m,1h),1.70(q,j=6.7hz,2h),1.37(t,j=7.1hz,3h),0.97(d,j=6.7hz,6h).esi-ms:m/z354.1[m+h]+.
2-3-4:1hnmr(400mhz,dmso)δ(ppm):9.09(s,1h),8.64(m,2h),7.42(d,j=8.8hz,1h),4.03(d,j=6.5hz,2h),2.77(s,3h),2.11(m,1h),1.59(s,9h),1.04(d,j=6.7hz,6h).esi-ms:m/z368.2[m+h]+.
2-3-5:1hnmr(400mhz,dmso)δ(ppm):9.05(d,j=5.7hz,1h),8.59(m,2h),7.40(dd,j=8.6,6.6hz,1h),4.25(dd,j=9.9,6.3hz,2h),2.75(s,3h),1.97–1.76(m,1h),1.76–1.65(m,2h),1.59(s,9h),1.10–0.24(s,j=6.6hz6h).esi-ms:m/z382.2[m+h]+.
2-3-6:1hnmr(400mhz,dmso)δ(ppm):9.08(s,1h),8.74–8.51(m,2h),7.40(d,j=9.6hz,1h),4.11(d,j=7.0hz,2h),2.77(s,3h),1.59(s,10h),1.31(tt,j=7.8,4.8hz,1h),0.69–0.52(m,2h),0.50–0.33(m,2h).esi-ms:m/z365.2[m+h]+.
2-3-7:1hnmr(400mhz,dmso)δ(ppm):9.07(s,1h),8.65–8.53(m,2h),7.39(d,j=8.9hz,1h),4.03(d,j=6.1hz,2h),2.76(s,3h),1.87–1.63(m,6h),1.58(s,9h),1.32–1.07(m,5h).esi-ms:m/z420.1[m+h]+.
2-3-8:m.p.138-140℃.1hnmr(400mhz,dmso)δ(ppm):9.10(s,1h),8.65(m,2h),7.44(d,j=8.7hz,1h),6.10(m,1h),5.50(d,j=17.3hz,1h),5.36(d,j=10.7hz,1h),4.86(s,2h),3.20–3.12(m,1h),2.78(s,3h),1.58(s,9h).esi-ms:m/z352.1[m+h]+.
2-3-9:m.p.129-131℃.1hnmr(400mhz,dmso)δ(ppm):9.10(s,1h),8.70–8.59(m,2h),7.55(d,j=9.1hz,1h),7.48–7.38(m,4h),5.35(s,2h),2.78(s,3h),1.58(s,9h),1.29(s,9h).esi-ms:m/z458.2[m+h]+.
2-3-10:m.p.133-136℃.1hnmr(400mhz,dmso)δ(ppm):9.10(s,1h),8.67(m,2h),7.46(m,6h),5.40(s,2h),2.78(s,3h),1.59(s,9h).esi-ms:m/z402.2[m+h]+.
2-3-11:m.p.137-139℃.1hnmr(400mhz,dmso)δ(ppm):9.08(s,1h),8.65(m2h),7.56(m,3h),7.28(m,2h),5.37(s,2h),2.77(s,3h),1.58(s,9h).esi-ms:m/z420.1[m+h]+.
2-3-12:m.p.143-145℃.1hnmr(400mhz,dmso)δ(ppm):9.09(s,1h),8.67(m,2h),7.64–7.36(m,5h),5.39(s,2h),2.77(s,3h),1.58(s,9h).esi-ms:m/z436.1[m+h]+.
2-3-13:m.p.148-149℃.1hnmr(400mhz,dmso)δ(ppm):9.10(s,1h),8.66(m,2h),7.65(m,2h),7.49(m,3h),5.38(s,2h),2.78(s,3h),1.59(s,9h).esi-ms:m/z481.1[m+h]+.
2-3-14:m.p.124-126℃.1hnmr(400mhz,dmso)δ(ppm):9.09(s,1h),8.65(m,2h),7.52(d,j=8.9hz,1h),7.40(d,j=7.7hz,2h),7.24(d,j=7.7hz,2h),5.33(s,2h),2.77(s,3h),2.32(s,3h),1.58(s,9h).esi-ms:m/z416.2[m+h]+.
2-3-15:m.p.197-199℃.1hnmr(400mhz,dmso)δ(ppm):9.10(s,1h),8.67(m,2h),7.93(d,j=7.9hz,2h),7.70(d,j=7.9hz,2h),7.51(d,j=9.5hz,1h),5.51(s,2h),2.78(s,3h),1.59(s,9h).esi-ms:m/z427.2[m+h]+.
2-3-16:m.p.158-159℃.1hnmr(400mhz,dmso)δ(ppm):9.09(s,1h),8.69–8.46(m,2h),7.57–7.40(m,2h),7.40–7.28(m,2h),7.21(m,1h),5.41(s,2h),2.77(s,3h),1.59(s,9h).esi-ms:m/z420.2[m+h]+.
2-3-17:m.p.157-159℃.1hnmr(400mhz,dmso)δ(ppm):9.10(s,1h),8.67(m,2h),7.49(m,4h),5.41(s,2h),2.77(s,3h),1.59(s,9h).esi-ms:m/z436.1[m+h]+.
2-3-18:m.p.140-141℃.1hnmr(400mhz,dmso)δ(ppm):9.06(s,1h),8.63(m,2h),7.72(s,1h),7.56–7.47(m,2h),7.41(t,j=7.8hz,1h),5.38(s,2h),2.75(s,3h),1.58(s,9h).esi-ms:m/z480.1[m+h]+.
2-3-19:m.p.114-116℃.1hnmr(400mhz,dmso)δ(ppm):9.08(s,1h),8.73–8.39(m,2h),7.51(d,j=9.4hz,1h),7.39–7.24(m,3h),7.19(d,j=6.8hz,1h),5.34(s,2h),2.77(s,3h),2.34(s,3h),1.58(s,9h).esi-ms:m/z416.2[m+h]+.
2-3-20:m.p.182-184℃.1hnmr(400mhz,dmso)δ(ppm):9.10(s,1h),8.68(m,2h),7.98(s,1h),7.86(d,j=7.7hz,2h),7.68(m,1h),7.53(d,j=8.8hz,1h),5.45(s,2h),2.78(s,3h),1.59(s,9h).esi-ms:m/z427.2[m+h]+.
2-3-21:m.p.136-138℃.1hnmr(400mhz,dmso)δ(ppm):9.09(s,1h),8.67(m,2h),7.72–7.53(m,2h),7.50–7.41(m,1h),7.31(dd,j=13.0,6.3hz,2h),5.43(s,2h),2.77(s,3h),1.59(s,9h).esi-ms:m/z420.1[m+h]+.
2-3-22:m.p.154-156℃.1hnmr(400mhz,dmso)δ(ppm):9.08(s,1h),8.80–8.47(m,2h),7.68(dd,j=5.6,3.7hz,1h),7.59–7.53(m,2h),7.49–7.27(m,2h),5.42(s,2h),2.77(s,3h),1.59(s,9h).esi-ms:m/z436.2[m+h]+.
2-3-23:m.p.167-168℃.1hnmr(400mhz,)δ(ppm):9.08(s,1h),8.71–8.55(m,2h),7.73(d,j=7.3hz,1h),7.67(dd,j=7.6,1.3hz,1h),7.54(d,j=8.9hz,1h),7.50(dd,j=10.9,4.1hz,1h),7.37(td,j=7.8,1.6hz,1h),5.37(s,2h),2.77(s,3h),1.59(s,9h).esi-ms:m/z482.1[m+h]+.
2-3-24:m.p.178-179℃.1hnmr(400mhz,dmso)δ(ppm):9.08(s,1h),8.73–8.49(m,2h),7.73–7.62(m,1h),7.61–7.53(m,2h),7.45(dd,j=5.8,3.5hz,2h),5.42(s,2h),2.77(s,3h),2.34(s,3h)1.59(s,9h).esi-ms:m/z416.2[m+h]+.
2-3-25:m.p.154-156℃.1hnmr(400mhz,dmso)δ(ppm):9.11(s,1h),8.85–8.53(m,2h),7.98(d,j=7.6hz,1h),7.87–7.75(m,2h),7.71–7.43(m,2h),5.54(s,2h),2.79(s,3h),1.59(s,9h).esi-ms:m/z427.1[m+h]+.
xx-2:m.p.196-197℃.1hnmr(400mhz,dmso)δ(ppm):13.58(s,1h),9.12(s,1h),8.72–8.53(m,2h),7.41(d,j=9.0hz,1h),4.24(t,j=6.4hz,2h),2.80(s,3h),1.88–1.65(m,2h),1.58–1.38(m,2h),0.97(t,j=7.4hz,3h).13cnmr(100mhz,dmso)δ(ppm):168.93,166.45,162.98,162.69,159.64,135.29,133.93,129.54,122.29,116.31,113.88,100.63,69.51,30.82,24.76,19.02,14.08.esi-ms:m/z310.1234[m-h]-.
xx-3:m.p.191-194℃.1hnmr(400mhz,dmso)δ(ppm):13.57(s,1h),9.13(s,1h),8.70–8.54(m,2h),7.45(d,j=8.9hz,1h),4.92(m,1h),2.80(s,3h),1.38(d,j=6.0hz,6h).13cnmr(100mhz,dmso)δ(ppm):168.94,166.45,162.73,162.09,159.66,135.22,134.16,129.36,122.27,116.49,114.79,102.32,72.53,24.77,22.04.esi-ms:m/z296.1043[m-h]-.
xx-4:m.p.193-194℃.1hnmr(400mhz,dmso)δ(ppm):13.60(s,1h),9.11(s,1h),8.60(m,2h),7.39(s,1h),4.01(s,2h),2.79(s,3h),2.11(m,1h),1.04(d,j=6.0hz,6h).13cnmr(100mhz,dmso)δ(ppm):168.92,166.42,162.99,162.67,159.62,135.25,133.84,129.52,122.19,116.21,113.84,100.64,75.53,28.08,24.76,19.18.esi-ms:m/z310.1189[m-h]-.
xx-5:m.p.198-202℃.1hnmr(400mhz,dmso)δ(ppm):13.56(s,2h),9.13(s,1h),8.76–8.34(m,2h),7.44(d,j=8.9hz,1h),4.27(t,j=6.4hz,2h),2.80(s,3h),1.83(m,j,1h),1.70(m,2h),0.97(d,j=6.5hz,6h).13cnmr(100mhz,dmso)δ(ppm):168.93,166.48,162.98,162.70,159.65,135.31,133.94,129.58,122.39,116.33,113.93,100.66,68.38,37.45,25.10,24.77,22.86.esi-ms:m/z324.1377[m-h]-.
xx-6:m.p.194-195℃.1hnmr(400mhz,dmso)δ(ppm):13.58(s,1h),9.14(d,j=5.2hz,1h),8.66(m,2h),7.51–7.27(m,1h),4.12(d,j=7.0hz,2h),2.81(s,3h),1.31(m,1h),0.72–0.54(m,2h),0.41(m,2h).13cnmr(100mhz,dmso)δ(ppm):168.96,166.48,163.0,162.73,159.68,135.29,134.03,129.55,122.34,116.47,114.1,100.08,74.26,24.77,10,22.esi-ms:m/z308.1042[m-h]-.
xx-7:m.p.217-218.0℃.1hnmr(400mhz,dmso)δ(ppm):13.59(s,1h),9.14(s,1h),8.65(m,2h),7.42(d,j=8.9hz,1h),4.05(d,j=6.0hz,2h),2.81(s,3h),1.92–1.61(m,6h),1.30–1.09(m,5h).13cnmr(100mhz,dmso)δ(ppm):168.92,166.42,162.99,162.67,159.62,135.25,133.84,129.52,122.19,116.21,113.84,100.64,75.53,28.08,24.76,19.18.esi-ms:350.1580m/z[m-h]-.
xx-8:m.p.216-217℃.1hnmr(400mhz,dmso)δ(ppm):13.58(s,1h),9.12(s,1h),8.63(m,2h),7.41(d,j=8.7hz,1h),6.10(m,1h),5.51(d,j=17.3hz,1h),5.36(d,j=10.5hz,1h),4.84(d,j=4.9hz,2h),2.80(s,3h).13cnmr(100mhz,dmso)δ(ppm):168.94,166.43,162.64,162.44,159.64,135.18,133.96,132.75,129.80,122.29,118.85,116.29,114.19,100.76,70.03,24.76.esi-ms:m/z294.0877[m-h]-.
xx-9:m.p.235-241℃.1hnmr(400mhz,dmso)δ(ppm):13.59(s,1h),9.14(s,1h),8.67(s,2h),7.47(ddd,j=33.9,18.5,8.6hz,7h),5.40(s,2h),2.81(s,3h).13cnmr(100mhz,dmso)δ(ppm):168.96,166.47,162.67,162.63,159.67,136.14,135.26,134.03,129.98,129.09,128.77,128.19,122.45,116.34,114.48,100.97,71.12,24.77.esi-ms:m/z344.1046[m-h]-.
xx-10:m.p.256-257℃.1hnmr(400mhz,dmso)δ(ppm):9.14(s,1h),8.77–8.58(m,2h),7.55(d,j=8.9hz,1h),7.50–7.31(m,4h),5.35(s,2h),2.81(s,3h),1.30(d,j=4.1hz,9h).13cnmr(150mhz,dmso)δ(ppm):168.96,166.50,162.70,162.64,159.67,150.33,135.28,134.03,133.09,129.88,128.20,125.87,122.47,116.38,114.42,100.88,70.99,34.83,31.56,24.79.14.08.esi-ms:m/z400.1666[m-h]-.
xx-11:m.p.244-247℃.1hnmr(400mhz,dmso)δ(ppm):13.60(s,1h),9.15(s,1h),8.69(m,2h),7.57(m,3h),7.28(m,2h),5.38(s,2h),2.81(s,3h).13cnmr(150mhz,dmso)δ(ppm):168.99,166.49,163.32,162.64,162.53,161.70,159.69,135.28,134.03,132.38,130.64,130.59,130.01,122.47,116.32,116.05,115.91,114.47,100.95,70.43,24.79.esi-ms:m/z362.0951[m-h]-.
xx-12:m.p.262-266℃.1hnmr(400mhz,dmso)δ(ppm):13.57(s,2h),9.15(s,1h),8.68(s,2h),7.61–7.39(m,4h),5.40(s,2h),2.81(s,3h).13cnmr(150mhz,dmso)δ(ppm):168.97,166.49,162.60,162.43,159.67,135.28,135.19,134.02,133.42,130.22,130.06,129.14,129.06,122.53,116.29,114.46,100.96,70.27,24.78.esi-ms:m/z378.0645[m-h]-.
xx-13:m.p.250-252℃.1hnmr(400mhz,dmso)δ(ppm):9.19(s,1h),8.83–8.61(m,2h),7.70(d,j=8.3hz,2h),7.55(m,4h),5.43(s,2h),2.86(s,3h).13cnmr(150mhz,dmso)δ(ppm):168.97,166.47,162.60,162.40,159.67,135.59,135.26,134.01,132.05,130.79,130.32,122.44,121.98,116.28,114.43,100.95,70.30,24.79.esi-ms:m/z422.0152[m-h]-.
xx-14:m.p.255-256℃.1hnmr(400mhz,dmso)δ(ppm):9.17(s,1h),8.69(m,2h),7.57(d,j=5.8hz,1h),7.37(m,4h),5.38(s,2h),2.85(s,4h),2.37(s,3h).13cnmr(150mhz,dmso)δ(ppm):168.90,166.57,162.63,159.62,138.16,135.19,133.97,133.06,129.89,129.64,128.38,122.66,116.36,114.43,100.90,71.07,24.77,21.27.esi-ms:m/z358.1210[m-h]-.
xx-15:m.p.263-272℃.1hnmr(400mhz,dmso)δ(ppm):9.14(s,1h),8.69(s,2h),7.93(d,j=7.9hz,2h),7.71(d,j=7.9hz,2h),7.51(d,j=9.5hz,1h),5.51(s,2h),2.81(s,3h).13cnmr(150mhz,dmso)δ(ppm):168.98,166.48,162.57,162.21,159.67,141.87,135.31,134.04,133.09,130.25,128.48,122.54,119.13,116.23,114.41,111.40,100.99,70.06,24.78.esi-ms:m/z369.1000[m-h]-.
xx-16:m.p.255-258℃.1hnmr(400mhz,dmso)δ(ppm):13.60(s,1h),9.15(s,1h),8.69(m,2h),7.60–7.42(m,2h),7.36(m,j=8.8hz,2h),7.26–6.85(m,1h),5.42(s,2h),2.81(s,3h).13cnmr(150mhz,dmso)δ(ppm):169.00,166.46,163.48,162.63,162.38,161.86,159.69,139.04,138.99,135.30,134.02,131.22,131.17,130.11,124.02,124.01,122.40,116.28,115.62,115.48,114.84,114.69,114.41,100.98,70.20,24.79.esi-ms:m/z362.0943[m-h]-.
xx-17:m.p.247-248℃.1hnmr(400mhz,dmso)δ(ppm):9.14(s,1h),8.79–8.46(m,2h),7.50(m,5h),5.41(s,2h),2.81(s,3h).13cnmr(150mhz,dmso)δ(ppm):168.91,166.53,162.54,162.34,159.64,138.69,135.29,134.01,133.71,131.05,130.16,128.70,127.88,126.68,122.68,116.28,114.41,100.97,70.13,24.77.esi-ms:m/z378.0674[m-h]-.
xx-18:m.p.240-241℃.1hnmr(400mhz,dmso)δ(ppm):9.15(s,1h),8.70(m,2h),7.74(s,1h),7.59(d,j=7.9hz,1h),7.58–7.51(m,2h),7.42(m,1h),5.41(s,2h),2.81(s,3h).13cnmr(100mhz,dmso)δ(ppm):168.96,166.46,162.57,162.36,159.66,138.93,135.29,134.02,131.59,131.31,130.75,130.14,127.05,122.27,116.26,114.41,100.99,70.09,24.76.esi-ms:m/z422.0136[m-h]-.
xx-19:m.p.239-241℃.1hnmr(400mhz,dmso)δ(ppm):9.13(s,1h),8.68(dd,j=7.6,2.1hz,2h),7.61–7.46(m,1h),7.41–7.26(m,4h),7.19(d,j=6.8hz,1h),5.35(s,2h),2.81(s,3h),2.34(s,4h).13cnmr(150mhz,dmso)δ(ppm):168.85,166.58,162.63,162.53,159.61,138.28,136.03,135.24,134.00,129.97,129.43,129.02,128.84,125.35,122.81,116.38,114.45,100.91,71.17,24.76,21.48.esi-ms:m/z400.1666[m-h]-.
xx-20:m.p.278-281℃.1hnmr(400mhz,dmso)δ(ppm):9.14(s,1h),8.68(m,2h),7.98(s,1h),7.85(m,2h),7.76–7.43(m,2h),5.45(s,2h),2.81(s,3h).13cnmr(150mhz,dmso)δ(ppm):168.97,166.45,162.55,162.22,159.65,137.87,135.30,133.99,132.86,132.56,131.56,130.43,130.18,122.44,119.06,116.23,114.34,112.08,101.98,69.88,24.78.esi-ms:m/z396.1029[m-h]-.
xx-21:m.p.262-263℃.1hnmr(400mhz,dmso)δ(ppm):13.64(s,1h),9.15(s,1h),8.79–8.43(m,2h),7.81–7.55(m,2h),7.48(d,j=6.5hz,1h),7.31(m,2h),5.44(s,2h),2.81(s,3h).13cnmr(100mhz,dmso)δ(ppm):168.92,166.52,162.58,162.37,162.12,159.65,135.30,134.04,131.35,131.07,130.21,125.20,122.98,116.21,116.15,115.94,114.39,100.96,65.68,24.75.esi-ms:m/z362.0991[m-h]-.
xx-22:m.p.260-273℃.1hnmr(400mhz,dmso)δ(ppm):13.53(s,1h),9.14(s,1h),8.70(m,2h),7.69(s,1h),7.58(d,j=8.8hz,2h),7.45(m,3h),5.44(s,2h),2.81(s,3h).13cnmr(150mhz,dmso)δ(ppm):168.96,166.49,162.58,162.33,159.66,135.34,134.05,133.52,133.21,130.82,130.54,130.21,130.05,128.01,122.53,116.22,114.36,100.90,68.78,24.79.esi-ms:m/z378.0688[m-h]-.
xx-23:m.p.277-279℃.1hnmr(400mhz,dmso)δ(ppm):13.58(s,1h),9.15(s,1h),8.70(dt,j=5.0,2.0hz,2h),7.70(dt,j=21.0,6.5hz,2h),7.57(d,j=8.9hz,1h),7.49(dd,j=12.9,6.0hz,1h),7.37(td,j=7.7,1.5hz,1h),5.39(s,2h),2.81(s,3h).13cnmr(150mhz,dmso)δ(ppm):168.97,166.48,162.60,162.32,159.67,135.36,135.09,135.06,134.07,133.31,133.21,131.21,131.08,130.73,130.21,128.54,123.41,122.51,121.35,116.23,116.19,114.39,114.34,100.96,100.90,70.92,24.79.esi-ms:m/z422.0166[m-h]-.
xx-24:m.p.262-263℃.1hnmr(400mhz,dmso)δ(ppm):13.58(s,1h),9.13(s,1h),8.80–8.41(m,2h),7.55(dd,j=38.3,7.7hz,2h),7.27(d,j=12.7hz,3h),5.38(s,2h),2.80(s,3h),2.39(s,3h).13cnmr(150mhz,)δ(ppm):168.98,166.45,162.66,162.63,159.67,137.33,135.24,134.06,134.00,130.80,129.91,129.03,126.37,122.31,116.32,114.41,100.82,69.95,24.80,18.98.esi-ms:m/z358.1226[m-h]-.
xx-25:m.p.235-236℃.1hnmr(400mhz,dmso)δ(ppm):9.15(s,1h),8.79–8.48(m,2h),7.98(d,j=7.6hz,2h),7.82(d,j=3.2hz,2h),7.69–7.47(m,2h),5.54(s,2h),2.82(s,3h).13cnmr(100mhz,dmso)δ(ppm):169.02,166.45,162.63,162.19,159.70,139.12,135.37,134.09,133.92,130.43,130.00,122.46,117.41,116.07,114.38,111.85,102.00,69.34,24.78.esi-ms:m/z396.1029[m-h]-.
实施例3
抑制黄嘌呤氧化酶活性的化合物xx-26的制备方法,包括以下步骤:
步骤1:向反应瓶中依次加入(2g,8.65mmol)3-氰基-4-异戊氧基-苯脒(sm2)、(2.95g,10.4mmol)(z/e)-2-{[(二甲氨基)亚甲基]}-4,4-二氟-3-氧代丁酸苄酯和20ml甲苯,升温回流反应3h,tlc监测反应结束,浓缩除去甲苯,得到中间体化合物3-1,不经纯化直接用于下一步;
步骤2:向上述浓缩物中加入20mldmf,加入10ml5%的naoh溶液,在60℃反应1h,tlc监测反应结束,加入1mhcl调ph=4,有大量固体析出,抽滤,滤饼在65℃鼓风干燥至恒重,用乙酸乙酯重结晶,得1.05g白色固体,即目的产物xx-26,收率32.0%。
得到的化合物xx-26进行融点、核磁及质谱检测,具体为:m.p.174-175℃.1hnmr(400mhz,dmso)δ(ppm):9.37(s,1h),8.86–8.47(m,2h),7.61(m,2h),4.30(t,j=6.1hz,2h),1.84(dd,j=12.4,6.4hz,1h),1.71(d,j=6.5hz,2h),0.97(d,j=6.4hz,6h).13cnmr(150mhz,dmso)δ(ppm):164.92,163.48,163.35,161.42,159.48,135.51,134.11,128.99,116.23,114.22,111.81,110.22,108.63,100.86,68.48,37.41,25.10,22.86.esi-ms:m/z360.1181[m-h]-.
根据化合物xx-27~xx-29的结构特点,选择相应的起始原料3-氰基-4-烷氧基-苯甲脒和反应原料,并采用实施例3的方法相应的制备化合物xx-27~xx-29。其中,反应原料选择(z/e)-2-[(二甲氨基)亚甲基]-4,4-二氟-3-氧代丁酸苄酯或(z/e)-2-[(二甲氨基)亚甲基]-4,4,4-三氟-3-氧代丁酸苄酯。对制备得到的化合物xx-27~xx-29进行熔点、核磁及质谱检测,具体如下:
xx-27:m.p.164-165℃.1hnmr(400mhz,dmso)δ(ppm):9.38(s,0h),8.84–8.56(m,1h),7.77–7.50(m,h),7.48(t,j=10.2hz,1h),7.00(d,j=8.2hz,1h),5.32(s,2h),3.78(s,2h).13cnmr(150mhz,dmso)δ(ppm):164.88,163.68,163.14,161.37,159.86,135.45,134.22,130.28,130.08,129.14,129.09,127.81,121.90,116.24,114.76,114.49,111.79,110.20,108.61,102.15,71.14,55.60.esi-ms:m/z410.0966[m-h]-.
xx-28:m.p.>290℃.1hnmr(400mhz,dmso)δ(ppm):8.97(s,1h),8.59(dd,j=8.9,2.2hz,1h),8.55(d,j=2.2hz,1h),7.44(d,j=9.0hz,1h),4.03(d,j=6.5hz,2h),2.12(dt,j=13.3,6.6hz,1h),1.04(d,j=6.7hz,6h).13cnmr(150mhz,dmso)δ(ppm):162.69,160.10,159.25,148.91,148.76,134.65,133.59,133.12,129.50,122.39,120.62,116.30,114.08,100.68,75.52,28.08,19.21.esi-ms:m/z364.0932[m-h]-.
xx-29:m.p.>290℃.1hnmr(400mhz,dmso)δ(ppm):8.99(s,1h),8.59(dd,j=8.9,2.2hz,1h),8.54(d,j=2.2hz,1h),7.46(d,j=9.0hz,1h),4.28(t,j=6.5hz,3h),1.85(m,1h),1.71(q,j=6.6hz,2h),0.97(d,j=6.6hz,6h).13cnmr(150mhz,dmso)δ(ppm):162.63,160.13,159.31,149.08,148.85,134.65,133.47,133.18,129.46,122.43,120.61,116.38,114.06,100.66,68.31,37.43,25.09,22.86.esi-ms:m/z378.1057[m-h]-.
实施例1~3制备的化合物的抑制黄嘌呤氧化酶活性的研究
1.试验材料
1.1试剂:黄嘌呤氧化酶(sigma,usa)、黄嘌呤(98.0%,百灵威科技有限公司)、焦磷酸钠(99.0%,天津市博迪化工有限公司)、乙二胺四乙酸二钠(99.0%,天津市博迪化工有限公司)。
1.2仪器:电子分析天平(ar1140型),电热恒温水浴锅(dk-98-1型),酶标仪(varioskanflash型)。
1.3受试样品:阳性药别嘌呤醇,制备的化合物x-1~xx-26、xx-1~xx-29。
2.试验方法
2.1配制方法
缓冲液的配制:以0.1mol/l焦磷酸钠和0.3mmol/ledta二钠配制缓冲液,ph值8.3。
化合物溶液配制:将受试样品先配制成0.1mm的dmso溶液,然后用缓冲液稀释成所需要的浓度进行测试。
黄嘌呤溶液配制:精密称取黄嘌呤30.42mg,置100ml量瓶中,先加入2ml的1m氢氧化钠溶液溶清,然后加入缓冲液稀释至刻度,得到浓度为2000μm的母液。依据需求用缓冲液稀释,体外活性测试黄嘌呤溶液浓度为500μm。
2.2酶活力检测方法
向96孔板中依次加入缓冲液67μl,黄嘌呤氧化酶溶液40μl,抑制剂溶液(配制的化合物溶液)53μl,25℃孵育15min后加入黄嘌呤溶液40μl(由于加入黄嘌呤反应即开始,所以加样应迅速且立刻测试,防止反应速率出现下降),之后每30s检测一次295nm处检测吸光度。空白组采用相应的药物溶剂做为对照。
v=(a2-a1)/t抑制率=(v空白-v测试)/v空白×100%
其中a1表示仪器在t1时刻所检测到反应液的吸光度;a2表示仪器在t2时刻所检测到反应液的吸光度;t表示两次读数间的时间间隔,可用公式t=t2-t1表示;v表示反应的速率:v空白表示反应液在不加黄嘌呤氧化酶抑制剂时的反应速率;v测试表示反应液在加入黄嘌呤氧化酶抑制剂时的反应速率。
以10μm为初筛浓度,对抑制率大于50%的化合物进行ic50测试。
2.2统计学方法
全部资料采用spss(17.0)统计软件包进行检验分析。结果用平均值±标准误差表示,组间均数比较进行方差齐性分析,并进行dunnett'stest分析方法进行组间比较。
3.实验结果
实验结果表明,本发明方法制得的化合物均显示出较强的黄嘌呤氧化酶抑制活性,可用作黄嘌呤氧化酶的抑制剂。实验数据见表1和表2。
表1化合物x-1~x-26对黄嘌呤氧化酶活性的影响(m±sd)
表2化合物xx-1~xx-29对黄嘌呤氧化酶活性的影响(m±sd)
实施例4
采用本发明方法制备得到的化合物x-10,制备黄嘌呤氧化酶抑制剂
处方组成及含量:
包衣液处方:
欧巴代(03b28796)21g
95%乙醇适量
制成约430ml
工艺
将己过100目筛的辅料与主药过60目筛混合,以95%乙醇制软材,以18目筛制粒,60℃通风干燥,以16目筛整粒后与硬脂酸镁混合均匀,以φ6mm浅凹冲打片。
包衣溶液的配制:在适宜容器中加入适量的95%乙醇,开动搅拌机,将处方量的欧巴代(03b28796)固体粉末均匀的加入到旋涡中,同时尽量避免有粉末漂浮在液体表面,必要时,可以提高转速以保持适当的旋涡,待所有的欧巴代(03b28796)全部加入后,降低搅拌速度,使旋涡消失,继续搅拌45min,即得。
薄膜包衣片的制备:将片芯置包衣锅内,保持温度60℃±5℃,进行包衣,即得。